Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis
A Latourte, C Cherifi, J Maillet, HK Ea… - Annals of the …, 2017 - ard.bmj.com
Objective To investigate the impact of systemic inhibition of interleukin 6 (IL-6) or signal
transducer and activator of transcription (Stat3) in an experimental model of osteoarthritis …
transducer and activator of transcription (Stat3) in an experimental model of osteoarthritis …
Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular.
F Legendre, P Bogdanowicz, K Boumediene… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: Studies have described elevated levels of interleukin 6 (IL-6) and its soluble
receptor (sIL-6R) in osteoarthritic and rheumatoid joints, as well as the inhibitory effect of this …
receptor (sIL-6R) in osteoarthritic and rheumatoid joints, as well as the inhibitory effect of this …
Implication of interleukin 18 in production of matrix metalloproteinases in articular chondrocytes in arthritis: direct effect on chondrocytes may not be pivotal
SM Dai, ZZ Shan, K Nishioka, K Yudoh - Annals of the rheumatic …, 2005 - ard.bmj.com
Objective: To clarify the effect of interleukin (IL) 18 on cartilage degeneration by studying the
profile of IL18 receptor (IL18R) on chondrocytes and the direct effect of IL18 on production of …
profile of IL18 receptor (IL18R) on chondrocytes and the direct effect of IL18 on production of …
[HTML][HTML] IL-1 in osteoarthritis: time for a critical review of the literature
TL Vincent - F1000Research, 2019 - ncbi.nlm.nih.gov
The concept of interleukin-1 (IL-1) as a target in osteoarthritis (OA) has been an attractive
one for many years. It is a highly potent inducer of cartilage degradation, causing the …
one for many years. It is a highly potent inducer of cartilage degradation, causing the …
Contribution of the interleukin‐6/STAT‐3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells
M Kondo, K Yamaoka, K Sakata… - Arthritis & …, 2015 - Wiley Online Library
Objective Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into
chondrocytes. Articular cartilage contains MSC‐like chondroprogenitor cells, which suggests …
chondrocytes. Articular cartilage contains MSC‐like chondroprogenitor cells, which suggests …
IL-1β and TNFα-initiated IL-6–STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis
T Mori, T Miyamoto, H Yoshida… - International …, 2011 - academic.oup.com
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint
damage and significant disability. However, the fundamental mechanisms underlying how …
damage and significant disability. However, the fundamental mechanisms underlying how …
Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 …
E Lubberts, LAB Joosten, MMA Helsen… - Cytokine, 1998 - Elsevier
Interleukin 10 (IL-10) and IL-4 are important downregulators of a number of macrophage
functions. The authors investigated the role of endogenous IL-4 and IL-10 and the …
functions. The authors investigated the role of endogenous IL-4 and IL-10 and the …
[HTML][HTML] TGF-β dampens IL-6 signaling in articular chondrocytes by decreasing IL-6 receptor expression
R Wiegertjes, A Van Caam, H Van Beuningen… - Osteoarthritis and …, 2019 - Elsevier
Objective Transforming growth factor-β (TGF-β) is an important homeostatic regulator of
cartilage. In contrast, interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in …
cartilage. In contrast, interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in …
Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction
LAB Joosten, E Lubberts, P Durez… - … : Official Journal of …, 1997 - Wiley Online Library
Objective. To examine the role of endogenous interleukin‐4 (IL‐4) and interleukin‐10 (IL‐
10) and the therapeutic effect of the addition of IL‐4 and IL‐10 in early and established …
10) and the therapeutic effect of the addition of IL‐4 and IL‐10 in early and established …
The combination of tumor necrosis factor α blockade with interleukin‐1 and interleukin‐17 blockade is more effective for controlling synovial inflammation and bone …
M Chabaud, P Miossec - … & Rheumatism: Official Journal of the …, 2001 - Wiley Online Library
Objective Anti–tumor necrosis factor α (anti‐TNFα) therapy has shown efficacy in the
treatment of rheumatoid arthritis (RA). Since interleukin‐1 (IL‐1), TNFα, and IL‐17 have …
treatment of rheumatoid arthritis (RA). Since interleukin‐1 (IL‐1), TNFα, and IL‐17 have …